Yale Obesity Research Center (Y-Weight)

New Capabilities

Home institution of the trial's lead investigator

People on the highest dose of Eli Lilly's experimental obesity drug lost an average of 30.3% of their body weight over 104 weeks — a result doctors previously saw almost only after bariatric surgery. The finding comes from TRIUMPH-1, a Phase 3 trial that randomized 2,339 adults with obesity or overweight to one of three doses of retatrutide or a placebo.

Updated Yesterday